Optimized Background Regimen (OBR): Clinical Trials

9 trials of Optimized Background Regimen (OBR), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 7 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1
Phase 33Active not recruiting 1, Completed 1, Terminated 1

Follow Optimized Background Regimen (OBR): new trials by email Literature Review of Optimized Background Regimen (OBR) trials Research Report on Optimized Background Regimen (OBR)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR) - HIV-1-infection
Phase 2RecruitingGilead Sciences122025-03-262026-04-24
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir - HIV-1-infection
Phase 2 / Phase 3Active not recruitingGilead Sciences722019-11-212026-10-01
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
ibalizumab, Optimized Background Regimen (OBR) - HIV
Phase 3CompletedTaiMed Biologics Inc.402015-08-012020-03-19
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
Levofloxacin, Optimized background regimen (OBR) - Tuberculosis, Multidrug-Resistant
Phase 2CompletedBoston University1112015-01-012023-05-24
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
Delamanid, Delamanid Pediatric Formulation (DPF), Optimized Background Regimen (OBR) - Multidrug Resistant Tuberculosis
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.372013-07-202020-11-23
Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
Delamanid, Optimized Background Regimen (OBR) - Tuberculosis
Phase 2TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.102010-02-192021-11-11
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
Etravirine (TMC125), Optimized background regimen (OBR) - HIV-1
Phase 2CompletedTibotec Pharmaceuticals, Ireland1032008-11-012015-04-23
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
Delamanid, Optimized Background Regimen (OBR), Placebo - Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.4812008-05-082021-12-01
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
tipranavir, ritonavir, Optimized Background Regimen (OBR) - HIV Infections
Phase 3TerminatedBoehringer Ingelheim332007-02-012014-06-27

Conditions studied

Tuberculosis, Multidrug-Resistant (4)  ·  Tuberculosis (3)  ·  Bacterial Infections (1)  ·  Extensively Drug-Resistant Tuberculosis (1)  ·  HIV Infections (1)  ·  Mycobacterium Infections (1)  ·  Tuberculosis, Pulmonary (1)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (3)  ·  Gilead Sciences (2)  ·  Boehringer Ingelheim (1)  ·  Boston University (1)  ·  TaiMed Biologics Inc. (1)  ·  Tibotec Pharmaceuticals, Ireland (1)

Countries

United States (6)  ·  South Africa (5)  ·  Canada (3)  ·  Spain (3)  ·  Argentina (2)  ·  Brazil (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Latvia (2)  ·  Peru (2)  ·  Philippines (2)  ·  Puerto Rico (2)  ·  Taiwan (2)

Top investigators

Anjanette Reyes-De Leon, MD (1)  ·  Charles R Horsburgh, MD (1)  ·  Louvina van der Laan, MD (1)  ·  Melchor VG Frias, IV, MD (1)

Results publications

PMID 22670901, PMID 26566161, PMID 29178937, PMID 30012767, PMID 30110589, PMID 30373800, PMID 35404075, PMID 35996282, PMID 40080768

NIH funding

2009 (1), 2019 (1), U01AI100805 (1)